| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$14,487 |
Change of Director's Interest Notice - Anthony Hall
|
26 Feb 2026 10:39AM |
$125.010 |
$138.670 |
risen by
10.93%
|
|
| Streamplay Studio Limited (SP8) ORDINARY FULLY PAID |
Communication Services |
$13 |
Streamplay H1 FY26 Results Summary
|
26 Feb 2026 10:38AM |
$0.010 |
$0.010 |
risen by
5.26%
|
|
| Streamplay Studio Limited (SP8) ORDINARY FULLY PAID |
Communication Services |
$13 |
Half Yearly Report and Accounts
|
26 Feb 2026 10:38AM |
$0.010 |
$0.010 |
risen by
5.26%
|
|
SP8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 85% to $8,502,721.
- Net profit after tax was $571,621, up from a loss of $177,809.
- Noodlecake Studios significantly contributed to revenue growth.
- Continued operations in Middle East & Africa and Asia Pacific.
- Cash and cash equivalents at $8.55 million as of 31 December 2025.
- Focus on cost management and operational efficiency.
- No dividends declared for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$58 |
Investor Presentation
|
26 Feb 2026 10:37AM |
$0.036 |
$0.050 |
risen by
38.89%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$662 |
FY2025 Full Year Results Q&A Webinar
|
26 Feb 2026 10:36AM |
$1.615 |
$1.650 |
risen by
2.17%
|
|
| Ambertech Limited (AMO) ORDINARY FULLY PAID |
Information Technology |
$11 |
Investor Presentation - 1H FY26 Results
|
26 Feb 2026 10:36AM |
$0.130 |
$0.115 |
fallen by
11.54%
|
|
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$505 |
Entitlement Offer Booklet
|
26 Feb 2026 10:34AM |
$1.860 |
$1.830 |
fallen by
1.61%
|
|
| Ardiden Limited (ADV) ORDINARY FULLY PAID |
Materials |
$86 |
Change in substantial holding
|
26 Feb 2026 10:33AM |
$0.495 |
$0.403 |
fallen by
18.69%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$165 |
ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
|
26 Feb 2026 10:27AM |
$0.041 |
$0.046 |
risen by
12.20%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of accelerated enrolment in XanaMIA phase 2b/3 Alzheimer's trial with 247 participants.
- Positive interim safety and efficacy analysis from DMC for XanaMIA trial.
- Open-label extension phase of XanaMIA trial to commence in Q1 2026.
- Agreement with FDA on streamlined design for pivotal trial of Xanamem 10 mg vs. placebo.
- Completion of commercial-grade manufacture of Xanamem tablets for OLE phase.
- Actinogen received $7.4 million R&D tax incentive for FY2025.
- Net loss of $11.3 million for half-year ended 31 December 2025, primarily due to R&D costs.
- Proforma cash balance of $29.7 million as of 31 December 2025.
- Planning for rapid expansion pending successful phase 2b/3 trial results.
- Xanamem shows promise as a treatment for Alzheimer's with potential safety and efficacy profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$165 |
Actinogen HY2025 financial report and Appendix 4D
|
26 Feb 2026 10:26AM |
$0.041 |
$0.046 |
risen by
12.20%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited reported a net loss after tax of $11,346,952 for the half-year ended 31 December 2025, compared to a loss of $8,168,979 for the previous year.
- The company's total revenue and other income increased to $2,107,063 from $244,406 the previous year.
- Research and development costs significantly increased to $8,902,759, reflecting ongoing clinical trials and development activities.
- The company's cash and cash equivalents decreased from $16,504,230 as of 30 June 2025 to $6,531,460 as of 31 December 2025.
- The total equity of Actinogen Medical Limited decreased from $18,335,903 as of 30 June 2025 to $8,368,615 as of 31 December 2025.
- The R&D tax rebate for FY25 amounted to $5,489,600 and was fully received by the company.
- The company issued new shares during the half-year, increasing contributed equity to $116,196,238.
- Actinogen launched an InvestorHub platform in September 2025 to enhance communication with investors.
- The report included a detailed statement of financial position and changes in equity, emphasizing the impact of R&D expenses and share-based payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wide Open Agriculture Ltd (WOA) ORDINARY FULLY PAID |
Consumer Staple |
$9 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 10:24AM |
$0.016 |
$0.014 |
fallen by
12.50%
|
|
WOA - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for half-year ended 31 December 2025 was $2,052,935.
- Revenue increased by 41% to $381,225 compared to the previous year.
- Focus on cost reduction and capital management to extend cash runway.
- $1.5 million in cash held as of 31 December 2025.
- Strong demand for lupin protein isolate and development of lupin oil and fiber.
- Exploration of contract manufacturing to meet demand and reduce costs.
- Directors believe the company will continue as a going concern.
- Potential R&D tax refund, equity raising, and asset disposals identified as financial strategies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$165 |
Change of Director's Interest Notice - David Haslingden
|
26 Feb 2026 10:22AM |
$0.540 |
$0.425 |
fallen by
21.30%
|
|
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$16 |
Media Release - December 2025 half-years results
|
26 Feb 2026 10:21AM |
$0.078 |
$0.068 |
fallen by
12.82%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for HY26 was $3.1 million, a 9% increase from the prior year.
- AUM grew by 7% to AUD 5.02 billion as of 31 December 2025.
- After-tax loss of $369,179 due to strategic investments.
- Focus on profitability and scalable growth.
- Strong financial position with $7.2 million in cash.
- Continued investment in team and operational capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$16 |
Half Yearly Report and Accounts
|
26 Feb 2026 10:20AM |
$0.078 |
$0.068 |
fallen by
12.82%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- K2 Asset Management Holdings Ltd reported a comprehensive loss of $369,179 for the half-year ended 31 December 2025.
- Total revenue for the half-year increased by 8.7% to $3,115,797 compared to the previous corresponding period.
- The company paid a final dividend of 0.50 cents per share, fully franked, on 30 September 2025.
- Employee benefits and marketing expenses were significant cost items impacting financial performance.
- No new equity issuances occurred during the half-year period.
- The company operates solely within Australia's financial services sector.
- Cash and cash equivalents decreased, affecting overall liquidity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Bond Exchange Holdings Limited (ABE) ORDINARY FULLY PAID |
Financials |
$2 |
Application for quotation of securities - ABE
|
26 Feb 2026 10:18AM |
$0.030 |
$0.013 |
fallen by
56.67%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,534 |
Final Director's Interest Notice - Graeme Barclay
|
26 Feb 2026 10:17AM |
$5.130 |
$5.230 |
risen by
1.95%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,534 |
Change of Director's Interest Notice - Phillip Britt
|
26 Feb 2026 10:15AM |
$5.130 |
$5.230 |
risen by
1.95%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,534 |
Change of Director's Interest Notice - Sarah Adam-Gedge
|
26 Feb 2026 10:15AM |
$5.130 |
$5.230 |
risen by
1.95%
|
|
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$115 |
Update - Dividend/Distribution - ANG
|
26 Feb 2026 10:15AM |
$0.183 |
$0.185 |
risen by
1.37%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,534 |
Change of Director's Interest Notice - Sue Klose
|
26 Feb 2026 10:15AM |
$5.130 |
$5.230 |
risen by
1.95%
|
|
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$132 |
BXN H1 FY2026 Results Presentation
|
26 Feb 2026 10:14AM |
$0.058 |
$0.058 |
fallen by
0%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue of $31.3 million for H1 FY2026, up 149% from PCP.
- Adjusted EBITDA of $8.3 million, an increase of 137% year-on-year.
- Upgraded FY2026 EBITDA guidance to $16.5-19 million.
- Expansion into new markets including the UK, Germany, and LATAM.
- New contracts with Curaleaf, Remidose, and Adrex.
- Significant investment in inventory to support future demand.
- World's largest GMP-certified cannabis pastilles facility.
- Dual listing completed on the Frankfurt Stock Exchange.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,534 |
Change of Director's Interest Notice - Adrian Fitzpatrick
|
26 Feb 2026 10:14AM |
$5.130 |
$5.230 |
risen by
1.95%
|
|
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$71 |
Botanix Webinar - 3 March - Registration Information
|
26 Feb 2026 10:13AM |
$0.057 |
$0.026 |
fallen by
54.39%
|
|
| RMA Global Limited (RMY) ORDINARY FULLY PAID |
Communication Services |
$26 |
Investor Update February 2026
|
26 Feb 2026 10:13AM |
$0.045 |
$0.039 |
fallen by
13.33%
|
|
RMY - Price-sensitive ASX Announcement
Full Release
Key Points
- RMA Global Limited focuses on the US real estate market with a strategy to increase penetration and market share.
- The company's new marketing approach emphasizes becoming a local authority and maintaining a consistent online presence.
- RMA Global highlights the importance of agent reviews and structured online presence for real estate success.
- The company offers tools and partnerships to real estate brokerages to enhance agent visibility and credibility.
- RMA Global targets a significant market opportunity valued at approximately AUD$341 million in the US.
- The presentation outlines a multi-year agreement with a network of 75,000 agents in the US and Canada.
- RMA Global's strategy includes automated systems for review collection and social media marketing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metro Mining Limited (MMI) ORDINARY FULLY PAID |
Materials |
$412 |
Webinar Invitation to Shareholders
|
26 Feb 2026 10:13AM |
$0.065 |
$0.067 |
risen by
3.08%
|
|
Call 1300 880 160
Start a chat
Schedule a call
